ADC Therapeutics (ADCT) Price to Sales (2021 - 2026)
ADC Therapeutics' (ADCT) quarterly Price to Sales came in at 7.08 in Q2 2026, down 55.73% year-over-year from 16.0 in Q2 2025, and down 69.02% quarter-over-quarter from 22.87 in Q1 2026.
Powered by 
Analysis
ADC Therapeutics (ADCT) Price to Sales (2021 - 2026) Analysis & Trends
ADC Therapeutics has disclosed Price to Sales across 6 years of filings, most recently posting 7.08 for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | ADC Therapeutics | 172.04 Mn | -47.07 Mn | 17.14 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.08 |
| Mar 31, 2026 | 22.87 |
| Sep 30, 2025 | 27.42 |
| Jun 30, 2025 | 16.00 |
| Mar 31, 2025 | 6.07 |
| Sep 30, 2024 | 16.50 |
| Jun 30, 2024 | 17.51 |
| Mar 31, 2024 | 20.59 |
| Sep 30, 2023 | 5.53 |
| Jun 30, 2023 | 9.93 |
| Mar 31, 2023 | 9.14 |
| Sep 30, 2022 | 4.85 |
| Jun 30, 2022 | 35.32 |
| Mar 31, 2022 | 24.27 |
| Sep 30, 2021 | 158.50 |
| Jun 30, 2021 | 496.85 |